Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke N Robinson

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|August 4, 2006
ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liverLin Ma, Luke N Robinson, Howard C Towle
Frontiers in Molecular Biosciences|April 24, 2023
Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic developmentSteven Pregizer, Thom Vreven, Mohit Mathur, et al.
Electrophoresis|April 24, 2012
Harnessing glycomics technologies: integrating structure with function for glycan characterizationLuke N Robinson, Charlermchai Artpradit, Rahul Raman, et al.
Virus Research|May 28, 2013
Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particlesCharlermchai Artpradit, Luke N Robinson, Boris K Gavrilov, et al.
Journal of Molecular Recognition : JMR|February 15, 2019
Structural prediction of antibody-APRIL complexes by computational docking constrained by antigen saturation mutagenesis library dataAndrew M Wollacott, Luke N Robinson, Boopathy Ramakrishnan, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2013
Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potencyKannan Tharakaraman, Luke N Robinson, Andrew Hatas, et al.
Antiviral Research|May 23, 2017
Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primatesEugenia Z Ong, Yadunanda Budigi, Hwee Cheng Tan, et al.
Plos Neglected Tropical Diseases|February 10, 2018
Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E proteinYadunanda Budigi, Eugenia Z Ong, Luke N Robinson, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 18, 2026
Selective Impact on Regulatory T cell with Sustained Functional Phenotype by the IL-2 Mutein VIS171 in a Nonhuman Primate ModelDavide Schiliró, Matt Tunbridge, Nolan J Brown, et al.
Cell|July 21, 2015
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant EpitopeLuke N Robinson, Kannan Tharakaraman, Kirk J Rowley, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|August 4, 2006
ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liverLin Ma, Luke N Robinson, Howard C Towle
Frontiers in Molecular Biosciences|April 24, 2023
Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic developmentSteven Pregizer, Thom Vreven, Mohit Mathur, et al.
Electrophoresis|April 24, 2012
Harnessing glycomics technologies: integrating structure with function for glycan characterizationLuke N Robinson, Charlermchai Artpradit, Rahul Raman, et al.
Virus Research|May 28, 2013
Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particlesCharlermchai Artpradit, Luke N Robinson, Boris K Gavrilov, et al.
Journal of Molecular Recognition : JMR|February 15, 2019
Structural prediction of antibody-APRIL complexes by computational docking constrained by antigen saturation mutagenesis library dataAndrew M Wollacott, Luke N Robinson, Boopathy Ramakrishnan, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2013
Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potencyKannan Tharakaraman, Luke N Robinson, Andrew Hatas, et al.
Antiviral Research|May 23, 2017
Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primatesEugenia Z Ong, Yadunanda Budigi, Hwee Cheng Tan, et al.
Plos Neglected Tropical Diseases|February 10, 2018
Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E proteinYadunanda Budigi, Eugenia Z Ong, Luke N Robinson, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 18, 2026
Selective Impact on Regulatory T cell with Sustained Functional Phenotype by the IL-2 Mutein VIS171 in a Nonhuman Primate ModelDavide Schiliró, Matt Tunbridge, Nolan J Brown, et al.
Cell|July 21, 2015
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant EpitopeLuke N Robinson, Kannan Tharakaraman, Kirk J Rowley, et al.
Pageof 1